Machine Learning Deconvolution of the Blood Brain Barrier Immune Fibrosis in the Pathogenesis of Neurodegenerative Diseases

How to Cite

1.
Husna Irfan Thalib. Machine Learning Deconvolution of the Blood Brain Barrier Immune Fibrosis in the Pathogenesis of Neurodegenerative Diseases. sjrmu [Internet]. 2025 Sep. 14 [cited 2025 Sep. 15];29(1). Available from: https://www.supp.journalrmc.com/index.php/public/article/view/426

Abstract

Background and Objectives: Neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) involve blood–brain barrier (BBB) dysfunction and immune-driven fibrosis, which contribute to neuronal injury and cognitive decline. This study used machine-learning (ML) deconvolution to examine immune and fibrotic signatures at the BBB, aiming to identify biomarkers and therapeutic targets for neurodegeneration.

Methods: Transcriptomic data from brain endothelial cells, cerebrospinal fluid, and peripheral blood of AD and PD patients were analyzed using ML deconvolution algorithms (CIBERSORTx and single-cell RNA sequencing). Immune subsets and fibrotic gene expression were quantified and integrated with clinical profiles. Clustering and predictive modelling identified immune-fibrotic subtypes, and biomarker findings were validated in external datasets with pathway-enrichment analyses.

Results: ML analysis revealed increased macrophages and activated endothelial cells expressing TGF-β, collagen I, and fibronectin at the BBB in both AD and PD. Peripheral monocytes migrated into the CNS, promoting fibrosis. High TGF-β signaling correlated with greater cognitive decline. Two subtypes emerged: (1) an inflammation-dominant subtype with elevated IL-6, TNF-α, marked BBB disruption, and rapid disease progression; and (2) a fibrosis-dominant subtype characterized by excessive collagen deposition, reduced BBB permeability, slower progression, and higher treatment resistance.

Conclusion: Machine-learning deconvolution highlights distinct immune and fibrotic alterations at the BBB in AD and PD. The inflammation-dominant subtype shows accelerated BBB breakdown and cognitive decline, whereas the fibrosis-dominant subtype exhibits slower progression but greater therapy resistance. These findings support the development of personalized, subtype-specific treatment strategies for neurodegenerative diseases.